Personal Paper
What's wrong with the funding of cancer research? PHILIP 
HUGH-JONES
I fear that what I am writing may sound like the complaints of a failed examination candidate, but I am distressed by my experience of trying to get money to support some cancer research. I have no training in oncology, but have considerable experience in research in thoracic medicine.
It all started when I went, and was fascinated by, an exhibition called "Light Fantastic" at Burlington House some years ago, which showed the principles of the laser and the development of holography. At that time we were one of the first hospitals to change from rigid to fibreoptic bronchoscopy for most patients. We have a large bronchoscopy list of up to 20 patients a week, nmany of whom regretfully have lung cancer. It seemed to me that shining a laser down a fibre light guide in the biopsy channel of a bronchoscope might be a good way of concentrating destructive energy locally into a tumour which, after all, arises within the bronchus. It always has seemed a pity to have to operate surgically or to use x-rays through the entire chest to get at a tumour in the airway. Furthermore, if hypoxic cells within a bronchial carcinoma would take up a dye, because of their damaged membranes, then by using the complementary wavelength light from an appropriate laser it might be possible to destroy preferentially tumour cells compared with others. Possibly a naive idea, but with hindsight, I think not.
So, early in 1977 two of us borrowed a pulsed ruby laser from a commercial firm for some pilot experiments and did a search of the world literature on laser action on biological tissues. We discovered that a Neodymium-YAG (Nd-YAG) laser gave better penetration than a ruby laser so, later that year, we applied to the Cancer Research Campaign for support. The application was rejected, so we had to borrow an experimental Nd-YAG laser, which had an erratic output. We then had the fortune to cooperate with an eminent cancer research expert who had worked on transplanting non-immunising breast carcinoma to the skin of mice, as an experimental model, to try out the effects of the King's College Hospital, London SE5 8RX PHILIP HUGH-JONES, MD, FRCP, consultant physician laser. At first he was rightly cautious about the project, but was finally convinced by experiment that the YAG laser might indeed have a place in the treatment of lung cancer.
Thus, early in 1978, I put up the idea of comparing the direct action of a YAG laser with that of photo-activation of dyes to the Medical Research Council as part of an application for renewal of a programme grant we had enjoyed on our research unit for different lung diseases. After the elapse of many months and a supplementary application (partly because they had lost the original) they rejected the programme grant but seemed impressed enough with some of its contents to suggest I might re-apply, using them as separate project grants. This I did but, in spite of evidence from the current literature at that time about the likely use of lasers and dye uptake, they rejected the laser project. I was surprised enough to ask to visit the Medical Research Council head office to inquire the reason, but I was told that it was not their policy to reveal reasons for rejection of grant applications, though they did suggest verbally that I might like to apply to a cancer research foundation. Firstly, a Nd-YAG laser used for its heating effects in the infra-BRITISH MEDICAL JOURNAL VOLUME 284 1 MAY 1982 red. It is of proved value for stopping haemoptysis and also for immediately giving an airway when other treatment has failed. Secondly, and more importantly, if haematoporphyrin D(HpD) is injected intravenously in man it is taken up by cancer and normal tissues but cleared from the latter more quickly, so that at about 72 hours after the injection it is concentrated differentially within the cancer cells. If then an appropriate red light (at 636 nm from a rhodamine-dye laser driven by an argon laser) is made to illuminate the tumour mass, by inserting a glass fibre down a bronchoscope into the tumour, the tumour cells are killed.
The value of a YAG laser for palliation of advanced lung cancer when radiotherapy has failed is already amply proved. Its value for earlier cases has yet to be found, but the work on hyperthermia in conjunction with radio-sensitisers and chemotherapeutic agents at Stanford University and elsewhere in the USA suggests that the very work we had proposed with a YAG laser might show that it is of value in earlier cases.
The value of photo-activation of HpD by a rhodamine-dye/ argon laser is equally proved. At Roswell Park Centre, in Buffalo, in Los Angeles, and, I believe at the Mayo Clinic, it is in routine use. It is similarly in routine use in Japan (where they have already shown that some inoperable lung cancers can be rendered operable) and in other countries. But its full use and place in relation to surgery, radiotherapy, and chemotherapy are yet to be determined. In my view its introduction could be as important as that of the introduction of ionising radiation, for it can be used for many different types of cancer in many different parts of the body, some not readily treatable by any other means. Because there are no cumulative effects many treatments can be given over a length of time to control a cancer. I do not know whether it is being used clinically in this country for other types of cancer because I do not deal with such patients, but it is certainly not being used endobronchoscopically for lung cancer.
British lack ofinterest
Why the lack of interest in Britain? I do realise that assessing a flood of grant applications when money is limited is a thankless and invidious task, but why all the secrecy from the Medical Research Council? Surely a failed applicant can be told either that his project failed on scientific grounds and preferably told why, so that he does not waste more time, or that it was a good idea but that there were no funds to support it. This is especially important as I suspect grant applications rejected by the Medical Research Council may be prejudiced in relation to other potential supporters.
It could well be that the projects we suggested were poor ones, though I think I can prove that they were not. I do not claim that we would have initiated work with HpD had we had support for our original application four years ago, but we would have been using it, as well as the Neodymium-YAG laser, I feel I should not still have to be begging for the hire of a now obsolete German Nd-YAG laser, even though the manufacturers have been most accommodating, because new British or German equipment can be bought outright and its maintenance will be more satisfactory. Patients should not have to be sent home because of equipment failure. I also want to proceed with what we suggested four years ago-namely, to use a dye laser for photoactivation of HpD, now that the technique seems so hopeful. And I think other competent centres in Britain should also have appropriate lasers available. Yes, the capital cost for us to start a complete programme of research and find a place of phototherapy with both types oflaser treatment, and concurrently to provide a clinical service, would be large-about J70 000 to do it all properly. But even that is little compared with the cost of some equipment used for cancer therapy; and it would only need about half that amount for a less ambitious programme in some of the centres.
Was there no money for this work? It seems to me that there was plenty available for cancer research. According to the Handbook of British Medical Research Charities the two cancer bodies, Imperial Cancer Research Fund and Cancer Research Campaign, had between them in 1981 joint capital assets of no less than C58 600 000 and a joint income for that year of £29 750 723. Yet we couldn't get the £17 000 required, then, to buy an obsolete German laser. I must support the Cancer Research Campaign to the extent that they do give out all the money they get for research, and were even overspent in 1981. In the past, the Imperial Cancer Research Fund was criticised, rightly in my view, for spending too little of the money it received from charity directly on research. For example, in 1979 and 1981, respectively, it had incomes ofC9-7m and £16l1m but gave out only £6-2m and f14-8m. Thus if it did not distribute over £5 000 000 in those two years, which are the only ones I know about, no wonder its capital assets are so large. A recent article in Nature,' however, states that even the Imperial Cancer Research Fund seems to be running short of cash, despite last year's income being the largest ever. This appears to be because it is spending no less than C3m towards a cyclotron, £12m towards building a new laboratory, and because government cuts have meant that some of its workers get less from other sources. But why is it the policy of the Imperial Cancer Research Fund to support only its own staff? Why should not the money collected from the public for cancer research be distributed for any competent research project, especially if it's a new endeavour, rather than the money being available only to a limited number of established workers ?
I would now like either to be told by the expert assessors why I have been wrong over the last four years and why the published work on phototherapy is unsatisfactory or, alternatively, for research and treatment in phototherapy to be supported in Britain as it is in many other countries. There ought to be money available between the Department of Health and Social Security, the Medical Research Council, the Imperial Cancer Research Fund, and the Cancer Research Campaign. What are the hazards of x-ray examinations in childhood?
In most diagnostic x-ray examinations the body tissues are exposed to relatively low doses of radiation. In many the dose delivered to important tissues, such as the gonads, amounts to only a tiny fraction of the dose received annually and unremittingly from natural sources of radiation in the environment. Furthermore, the dose rates most often used in diagnostic examinations fall within the range of exposure that has been proposed by both national and international protection bodies as acceptable annually in occupational exposure. At the low level of dose exposure encountered in diagnostic radiation, the untoward effects being considered are either genetic or carcinogenic. Bone marrow, breast, lung, and thyroid are the tissues most susceptible to the induction of cancer by irradiation. It is therefore essential that all reasonably practical steps are taken to minimise exposure to radiation. Requests for examinations, particularly those needing higher exposure, must be well justified medically. Patients and parents of children who require radiographic examinations should be reassured that the degree of risk to the individual patient for most routine examinations is very low. When examinations at higher exposures are needed the medical benefit is still expected to outweigh the risks of harm from radiation.1 2 There is evidence that, for the same absorbed dose, the risk of induced cancer may be appreciably higher in children compared with adults. For example, in leukaemia the risk of induction for the same dose exposure may be twice as great in children. Again, there is an appreciably higher risk of breast carcinoma arising in an adolescent breast that has been irradiated compared with other ages. It must be remembered, however, that the radiation dosage delivered during x-ray examinations of children are usually smaller than those received by adults. For example, the dose required for an adult chest radiograph may be greater than that received by a neonate by a factor of 10. At the same time, the relative small size of the child means that target organs such as thyroid and gonads may be much closer to the main beam. Clearly, special attention to minimising the dose in children is needed, for with a longer life expectancy they have a greater potential for the manifestations of the late effects of irradiation. Nevertheless, it should be emphasised that for the individual child the degree of risk of cancer induction from the normal range of doses used in diagnostic radiology is low. To place this in perspective, in a follow-up study of 1480 children who had had multiple cardiac fluoroscopy no increase of cancer above the expected rate was found.3 This study provided 26 000 years of patient follow-up. It does illustrate the difficulty of collecting meaningful data in a group of patients who have been exposed to diagnostic radiation, but where this has been done no significant deleterious effect has been shown. During the past 20 years attention has been focused on diminishing the exposure of everyone to radiation. It is therefore appropriate that strenuous efforts have been directed towards improving the standards in diagnostic radiology. In paediatric radiology special problems arise related to the need to define fields more carefully and the use of the immobilisation techniques to obtain an examination of high quality. Thus skilful radiography, advice from medical physicists on doses, and discussions with clinicians as to the importance of any particular examination all contribute to achieving high standards of practice. Interestingly, although the total number of radiological examinations in childhood have increased in recent years, the radiation dose per examination has decreased owing to these improved techniques.-M C PEARSON, consultant radiologist, London. 
